Center for Molecular Medicine Cologne

Dr. Paul Higgins - Curriculum Vitae

Education and Professional Career

since 2015: Research group leader on the Dynamics of Antimicrobial Resistance, and responsible for Molecular Typing and Outbreak Management Laboratory at the Institute of Medical Microbiology, Immunology and Hygiene, University of Cologne
since 2010: Principal investigator. DFG-FOR2251 (Forschergruppe); Adaptation and persistence of the emerging pathogen Acinetobacter baumannii
2007: Principal investigator. BMBF-funded project. Mechanism of carbapenem-resistance in Acinetobacter baumannii
2003 - 2007: Post-doctoral research fellow. Role of the efflux pump AdeB in the development of fluoroquinolone resistance
since 2003: University of Cologne; Institute for Medical Microbiology, Immunology and Hygiene (IMMIH)
2002: Post-doctoral research fellow at University of Düsseldorf investigating the comparative in vivo efficacy of moxifloxacin, levofloxacin and clarithromycin against Streptococcus pneumoniae
1998 - 2002: University of Edinburgh. PhD Medical Microbiology “Mechanisms of Fluoroquinolone Resistance in Acinetobacter spp.”
1994 - 1998: University of Edinburgh. BSc Hons Medical Microbiology

Awards, distinctions and professional activities

  • Member of ESCMID (European Society of Clinical Microbiology and Infectious Diseases) and BSAC (British Society for Antimicrobial Chemotherapy)
  • Associate editor BMC Infectious Diseases
  • Guest Associate Editor for “Infectious Diseases – Surveillance, Prevention and Treatment” Frontiers in Medicine, and Frontiers in Public Health, with the topic “Carbapenemase-Producing Organisms as Leading Cause of Hospital Infections”
  • Organising committee for the 9th, 10th, and 13th International Symposium on the Biology of Acinetobacter, Cologne 2013, Athens 2015, and Coimbra 2023, respectively.
  • I review grants for ESCMID, British Society for Antimicrobial Chemotherapy, The South African Medical Research Council, The British Medical Research Council, The French National Research Agency, The Netherlands Organisation for Health Research and Development, The Irish Research Council, The Croatian Science Foundation, The Wellcome Trust, and The United Kingdom Health Protection Agency.


Link to PubMed